| Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer AL Ho, RK Grewal, R Leboeuf, EJ Sherman, DG Pfister, D Deandreis, ... New England Journal of Medicine 368 (7), 623-632, 2013 | 889 | 2013 |
| Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522 KK Ang, Q Zhang, DI Rosenthal, PF Nguyen-Tan, EJ Sherman, RS Weber, ... Journal of clinical oncology 32 (27), 2940-2950, 2014 | 852 | 2014 |
| Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study EEW Cohen, LS Rosen, EE Vokes, MS Kies, AA Forastiere, FP Worden, ... Journal of Clinical Oncology 26 (29), 4708-4713, 2008 | 741 | 2008 |
| Transoral robotic surgery: radical tonsillectomy GS Weinstein, BW O’Malley, W Snyder, E Sherman, H Quon Archives of otolaryngology–head & neck surgery 133 (12), 1220-1226, 2007 | 690 | 2007 |
| Efficacy of Selpercatinib in RET-Altered Thyroid Cancers LJ Wirth, E Sherman, B Robinson, B Solomon, H Kang, J Lorch, F Worden, ... New England Journal of Medicine 383 (9), 825-835, 2020 | 669 | 2020 |
| Diffusion-weighted magnetic resonance imaging for predicting and detecting early response to chemoradiation therapy of squamous cell carcinomas of the head and neck S Kim, L Loevner, H Quon, E Sherman, G Weinstein, A Kilger, H Poptani Clinical Cancer Research 15 (3), 986-994, 2009 | 450 | 2009 |
| Relief of Feedback Inhibition of HER3 Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in BRAF-Mutant Thyroid Carcinomas C Montero-Conde, S Ruiz-Llorente, JM Dominguez, JA Knauf, A Viale, ... Cancer discovery 3 (5), 520-533, 2013 | 427 | 2013 |
| Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review SA Laurie, AL Ho, MG Fury, E Sherman, DG Pfister The lancet oncology 12 (8), 815-824, 2011 | 423 | 2011 |
| Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label … MS Brose, ME Cabanillas, EEW Cohen, LJ Wirth, T Riehl, H Yue, ... The lancet oncology 17 (9), 1272-1282, 2016 | 367 | 2016 |
| Randomized phase II trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma S McBride, E Sherman, CJ Tsai, S Baxi, J Aghalar, J Eng, WI Zhi, ... Journal of Clinical Oncology 39 (1), 30-37, 2021 | 293 | 2021 |
| Integrated genomic analysis of Hürthle cell cancer reveals oncogenic drivers, recurrent mitochondrial mutations, and unique chromosomal landscapes I Ganly, V Makarov, S Deraje, YY Dong, E Reznik, V Seshan, ... Cancer cell 34 (2), 256-270. e5, 2018 | 245 | 2018 |
| Prediction of response to chemoradiation therapy in squamous cell carcinomas of the head and neck using dynamic contrast-enhanced MR imaging S Kim, LA Loevner, H Quon, A Kilger, E Sherman, G Weinstein, A Chalian, ... American journal of neuroradiology 31 (2), 262-268, 2010 | 240 | 2010 |
| A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). KK Ang, QE Zhang, DI Rosenthal, P Nguyen-Tan, EJ Sherman, RS Weber, ... Journal of Clinical Oncology 29 (15_suppl), 5500-5500, 2011 | 221 | 2011 |
| The molecular landscape of recurrent and metastatic head and neck cancers: insights from a precision oncology sequencing platform LGT Morris, R Chandramohan, L West, A Zehir, D Chakravarty, DG Pfister, ... JAMA oncology 3 (2), 244-255, 2017 | 217 | 2017 |
| Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers LA Dunn, EJ Sherman, SS Baxi, V Tchekmedyian, RK Grewal, SM Larson, ... The Journal of Clinical Endocrinology & Metabolism 104 (5), 1417-1428, 2019 | 207 | 2019 |
| Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: an update of the Memorial Sloan-Kettering Cancer Center experience J Setton, N Caria, J Romanyshyn, L Koutcher, SL Wolden, MJ Zelefsky, ... International Journal of Radiation Oncology* Biology* Physics 82 (1), 291-298, 2012 | 206 | 2012 |
| Proton beam radiation therapy results in significantly reduced toxicity compared with intensity-modulated radiation therapy for head and neck tumors that require ipsilateral … PB Romesser, O Cahlon, E Scher, Y Zhou, SL Berry, A Rybkin, KM Sine, ... Radiotherapy and Oncology 118 (2), 286-292, 2016 | 201 | 2016 |
| Patterns of treatment failure and postrecurrence outcomes among patients with locally advanced head and neck squamous cell carcinoma after chemoradiotherapy using modern … JE Leeman, J Li, X Pei, P Venigalla, ZS Zumsteg, E Katsoulakis, ... JAMA oncology 3 (11), 1487-1494, 2017 | 186 | 2017 |
| Dissecting anaplastic thyroid carcinoma: a comprehensive clinical, histologic, immunophenotypic, and molecular study of 360 cases B Xu, T Fuchs, S Dogan, I Landa, N Katabi, JA Fagin, RM Tuttle, ... Thyroid 30 (10), 1505-1517, 2020 | 182 | 2020 |
| Dynamic contrast-enhanced magnetic resonance imaging as a predictor of outcome in head-and-neck squamous cell carcinoma patients with nodal metastases A Shukla-Dave, NY Lee, JFA Jansen, HT Thaler, HE Stambuk, MG Fury, ... International Journal of Radiation Oncology* Biology* Physics 82 (5), 1837-1844, 2012 | 175 | 2012 |
